<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21758">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986712</url>
  </required_header>
  <id_info>
    <org_study_id>Merck MISP 50422</org_study_id>
    <nct_id>NCT01986712</nct_id>
  </id_info>
  <brief_title>An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron</brief_title>
  <official_title>An Observational Pilot Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon Alfa Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjiv Agarwala, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's Hospital and Health Network, Pennsylvania</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the compliance with and perceptions of treatment, as well as health-related
      quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluate Compliance with Standard High Dose Interferon (HDI) versus Sylatron</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate compliance with administration of standard HDI versus PEG IFN for patients with surgically resected melanoma in need of adjuvant therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare Quality of Life (Qol)for patients on HDI versus PEG IFN</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare QOL for patients on standard HDI versus PEG IFN using chemotherapy convenience and satisfaction questionaire (CCSQ) and to evaluate the treatment-related side effects that may impact the patients health-related QOL using Functional Assessment of Cancer Therapy of Biologic Response Modifier (FACT-BRM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the frequency of Grade 3 and Grade 4 Toxicities</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the frequency of Grade 3 and 4 toxicities, according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) for patients on standard HDI versus PEG IFN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the Reasons for Patients' Choice of Treatment with HDI versus PEG IFN</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To examine reasons for patients' choice of treatment HDI versus PEG IFN, for those case in which patients are presented with a choice of either treatment option</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Intron A, HDI</arm_group_label>
    <description>High-dose interferon alfa (Intron A, HDI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sylatron</arm_group_label>
    <description>Pegylated alfa-interferon 2b (Sylatron, PEG IFN)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with surgically resected melanoma receiving adjuvant therapy with HDI or PEG IFN
        thherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female at least 18 years of age

          -  Patient has had surgically resected melanoma and plans to                receive
             adjuvant therapy with HDI or PEG IFN

          -  Patient is willing and able to give written informed consent

          -  Patient is willing to comply with all study requirements

        Exclusion Criteria:

          -  Patient is unable or unwilling to complete QoL questionaire or compliance   diary

          -  Patient has a history of anaphylaxis due to any interferon alpha product

          -  Patient has autoimmune hepatitis

          -  Patient has decompensated liver disease (Child-Pugh score&gt;6 ( Class B and C)

          -  Patient has a history of neuropsychiatric disorder (including depression) that, in
             the judgment of the investigator, may impair the patient's ability to successfully
             complete treatment or protocol-related requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Agarwala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's University Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rose Cabral, RN, BSN, OCN</last_name>
    <phone>484-503-4151</phone>
    <email>Rosemarie.Cabral@sluhn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Butryn, MS, CCRP</last_name>
    <phone>484-526-5190</phone>
    <email>Tracy.Butryn@sluhn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Luke's University Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose M Cabral, RN</last_name>
      <phone>484-503-4151</phone>
      <email>Rosemarie.cabral@sluhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Sanjiv Agarwala, MD</last_name>
      <phone>484-503-4500</phone>
      <email>Sanjiv.agarwala@sluhn.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Hospital and Health Network, Pennsylvania</investigator_affiliation>
    <investigator_full_name>Sanjiv Agarwala, MD</investigator_full_name>
    <investigator_title>Chief of Medical Oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
